Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels …
Post
-
-
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) …
-
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder Ayrmid …
-
Big pharma pushes for European policy change as tariffs loom
Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump "threaten" billions of …
-
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment of …
-
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
The US Advisory Committee on Immunization Practices (ACIP) has voted to recommend the use of respiratory syncytial virus (RSV) vaccines, …
-
Trump order eases Medicare price negotiation for small molecule drugs
US President Donald Trump has issued a broad executive order to lower prescription drug prices in the country, notably including …
-
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical …
-
WHO member states agree on treaty to fight future pandemics
Member states of the World Health Organization (WHO) have reached an agreement on how to tackle future pandemics courtesy of …
-
Podcast: What’s next for the pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans …
-
The GLP-1 drug shortage is over. What’s next for the compounders?
“I am taking compounded semaglutide that I ordered online, but I don’t know how long I will have access to …
-
EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This …
-
Mural shuts down lead programme and slashes 90% of staff
Mural Oncology is winding down its lead clinical programme and enacting sweeping cuts to its workforce after its experimental cancer …
-
Irish pharmaceutical exports to US soar amid tariff concerns
Irish medical and pharmaceutical exports to the US have seen a significant surge, with a year-on-year increase above 450% in …
-
The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033
Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the …
